Led · Series A · Jul 2020

Orpyx builds the Sensory Insole system that integrates multi-modal sensor technology with a dedicated team of specialized nurses to enable continuous remote monitoring of plantar pressure, temperature, activity, and adherence. The system is used to prevent diabetic foot ulcers (DFU) and lower-limb amputations by empowering patients with personalized remote care. Orpyx partners with U.S. health plans and organizations such as the Veterans Health Administration to deploy its solution. The company announced an additional $20 million in growth capital to accelerate its commercial efforts and expand patient access. Orpyx positions itself as a leader in DFU and amputation prevention and emphasizes improving mobility and healthspan for people with diabetes and peripheral neuropathy. The company lists New York and Calgary, Alberta in its announcement and focuses on scaling clinical and payer relationships. Orpyx Medical Technologies develops the Orpyx SI Sensory Insoles, a sensory insole with telemedicine capabilities that delivers real-world plantar pressure feedback and real-time analytics to help prevent diabetic foot and neuropathy-related ulcers. The technology also provides clinical-grade plantar pressure data for researchers in sports medicine, therapeutic applications and footwear design. Led by Dr. Breanne Everett, CEO and co‑inventor, the company plans to use new funding to expand North American commercialization and to broaden and accelerate technology development. Orpyx is based in Calgary, Canada. The company closed a $7.6M Series A round in 2020, bringing total funding since inception to $18.5M.